Essential Thrombocythemia Et Market Insights

DelveInsight’s ‘Essential Thrombocythemia (ET)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Essential Thrombocythemia (ET), historical and forecasted epidemiology as well as the Essential Thrombocythemia (ET) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Essential Thrombocythemia (ET) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Essential Thrombocythemia (ET) market size from 2017 to 2030. The Report also covers current Essential Thrombocythemia (ET) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan


Study Period: 2017–2030


Essential Thrombocythemia (ET) Disease Understanding and Treatment Algorithm


Essential Thrombocythemia (ET) Overview

According to the MPN Research Foundation, Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increased number of platelets in the blood. The overproduction (megakaryocytic hyperplasia) of platelet-forming cells, called “megakaryocytes,” in the marrow results in the release of too many platelets into the blood.

The term “essential” indicates that the increase in platelets is an inherent problem of the blood cell production in the bone marrow and “Thrombocythemia” refers to an excess of platelets in the blood. Also, the increased platelet count may result in the blockage in blood vessels (thrombus), splenomegaly, and hemorrhagic episodes. Most cases of ET are not inherited, and it arises from gene mutations that occur in early blood-forming cells after conception. However, in very rare cases, ET is inherited in an autosomal dominant pattern and known as familial Essential Thrombocythemia.


The typical pattern of ET onset is bimodal, with one peak occurring during young adulthood in females and the other peak occurring between the ages of 50–70 years in both males and females. The incidence of ET is around 1.5–2 times higher in females as compared to males.


Essential Thrombocythemia (ET) Diagnosis

The diagnosis of ET is based on the complete blood count, blood smear examination, genetic and bone marrow testing. Some of the patients may be asymptomatic and found to have an increased platelets count. By carefully examining the results of the above-mentioned diagnostic tests and by reviewing the patient’s clinical history and symptoms, a physician can diagnose ET.

Continued in the report…..


Essential Thrombocythemia (ET) Treatment

The objective of the treatment of ET is to prevent vascular complications such as thrombotic and hemorrhagic events because they are the leading causes of morbidity and mortality. The treatment strategy mostly depends on whether the patient is at low or high risk for thrombosis as risk stratification is used to determine the need for the patient to undergo the procedure. Generally, the low-risk patients are young with no prior thrombosis, whereas high-risk patients are older (over age 60) with a previous history of thrombosis.

Low-risk patients are recommended aspirin if there are no significant contraindications for the same. There should be a careful consideration of the possibility of acquiring von Willebrand disease when platelets are more than 1,000 × 109/L because, in the setting of abnormal von Willebrand laboratory parameters, aspirin should not be used. Aspirin is also the indicated treatment for a patient with microvascular thrombosis such as erythromelalgia. Also, antiplatelet and cytoreductive therapy is adopted for a high-risk patient.

Hydroxyurea is generally considered as the first-line drug for cytoreductive therapy. Anagrelide, on the other hand, is a second-line therapy used to reduce platelet count. Other drugs used in ET include radioactive phosphorous, pipobroman, interferon, and busulfan. These are still used in older patients who cannot tolerate hydroxyurea (Ashorobi & Gohari, 2019). There are currently four drugs to consider as second-line therapy in ET: pegylated interferon-α (IFN-α), busulfan, anagrelide, and pipobroman. Among these, the current choice for second-line therapy is pegylated IFN-α (starting dose 90 mcg SC weekly).

European LeukemiaNet recommends hydroxycarbamide (HC) as the first-line therapy but advises caution in patients <40 years. Anagrelide (Xagrid) is licensed in Europe for patients with ET intolerant/refractory to HC, and in some countries (i.e., USA, Japan) it is authorized as first-line therapy.


Essential Thrombocythemia (ET) Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Essential Thrombocythemia (ET), Total Prevalence of Essential Thrombocythemia Based on Symptoms, Gender-specific Diagnosed Prevalence of Essential Thrombocythemia, Age-specific Diagnosed Prevalence of Essential Thrombocythemia, Prevalence of Essential Thrombocythemia based on Risk, and Gene Mutation Specific Prevalence of Essential Thrombocythemia scenario of ET in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.


Key Findings

• As per DelveInsight’s analysis, the total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM was found to be 232,688 in 2017. The estimates higher prevalence of Essential Thrombocythemia (ET) in the United States with 142,635 cases in 2017.

• According to DelveInsight’s analysis, it has been observed that ET is mostly diagnosed in the age group of 60-80.

• Among EU5, France shows a higher prevalence of ET followed by Germany and the UK, Italy, and Spain respectively.

• Japan accounts second among the 7MM in terms of prevalent cases with 19,946 cases among the 7MM.


Essential Thrombocythemia (ET) Epidemiology

The epidemiology segment also provides the Essential Thrombocythemia (ET) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


Essential Thrombocythemia (ET) Drug Chapters

The drug chapter segment of the Essential Thrombocythemia (ET) report encloses the detailed analysis of ET marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Essential Thrombocythemia (ET) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.


Essential Thrombocythemia (ET) Marketed Drugs


Agrylin/Xagrid: Shire

Agrylin (anagrelide HCI) is the first drug approved for the treatment of Essential Thrombocythemia (ET). It is a platelet-reducing agent, with chemical name 6, 7-dichloro- 1, 5-dihydroimidazo [2, 1-b] quinazolin-2(3H)-1 monohydrochloride monohydrate. Bristol-Myers Squibb originally developed the drug, but in 1999, Roberts Pharmaceutical purchased all rights of Agrylin from them, and later Shire Plc acquired Roberts Pharmaceutical. Hence, now Shire Plc holds the rights for agrylin. The drug is approved under the name xagrid in Europe, and as agrylin in the US and Japan.

Products detail in the report…


Thromboreductin: AOP Orphan Pharmaceuticals

Thromboreductin is an innovative treatment option for patients afflicted by Essential Thrombocythemia (ET), a rare but severe bone marrow disease. The active ingredient in thromboreductin, which helps in lowering the blood platelet count and reduces the risk of complications, is anagrelide. This drug is not associated with a possible risk of leukemogenesis, as is currently the case with cytostatic agents. Treatment with this drug, if successful, could help patients have an almost normal life expectancy.

Products detail in the report…


Essential Thrombocythemia (ET) Emerging Drugs


Ropeginterferon alfa-2b (P1101): PharmaEssentia

Ropeginterferon alfa-2b (P1101) is a novel, long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties offering improved tolerability and convenience. It is discovered and manufactured by PharmaEssentia in a Taichung plant, which was cGMP certified by EMA in January 2018. Ropeginterferon alfa-2b is designed to be the purer interferon-alpha designed; other interferon alphas on the market currently include PEG-Intron (Merck) and Pegasys (Roche).

Products detail in the report…


Jakavi (ruxolitinib): Novartis

Jakavi (ruxolitinib) is an oral JAK1/JAK2 inhibitor with clinical benefit in patients with other MPNs, myelofibrosis (MF), ET, and PV. It is approved by the European Commission for the treatment of adult patients with PV who are resistant to or intolerant of hydroxyurea and for the treatment of disease-related splenomegaly or symptoms in adult patients with primary MF (also known as chronic idiopathic MF), post-PV MF or post-ET MF. The exact indication for Jakavi varies by country. Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the United States. Jakavi is marketed in the United States by Incyte Corporation as Jakafi for patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.

Products detail in the report…


Bomedemstat (IMG-7289): Imago BioSciences

Bomedemstat (IMG-7289) is a small molecule discovered by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme essential for the production and normal function of megakaryocytes and self-renewal of malignant hematopoietic stem or progenitor cells. Megakaryocytes are the primary producer of platelets and cytokines that drive essential thrombocythemia pathogenesis. Currently, bomedemstat is being tested in clinical studies as a potentially disease-modifying monotherapy for MF, ET, and related indications.

Products detail in the report…

List to be continued in the report…


Essential Thrombocythemia (ET) Market Outlook

ET is associated with an increased risk of thrombohemorrhagic complications and transformation to myelofibrosis (MF) or acute leukemia (AL). Cytoreductive therapy (CRT) is used to reduce thrombosis and hemorrhage in high-risk ET. The CRT treatment includes the use of CRT, anagrelide, hydroxycarbamide, busulfan, interferon-α (IFN), pegylated interferon, pipobroman and sodium phosphate (P32).

Low-risk patients are recommended aspirin if there are no significant contraindications for the same. There should be a careful consideration of the possibility of acquiring von Willebrand disease when platelets are more than 1,000 × 109/L because, in the setting of abnormal von Willebrand laboratory parameters, aspirin should not be used. Aspirin is also the indicated treatment for a patient with microvascular thrombosis such as erythromelalgia. Also, antiplatelet and cytoreductive therapy is adopted for a high-risk patient.

Pregnant patients with ET are recommended to use low molecular weight heparin during pregnancy for 6 weeks after delivery in addition to cytoreduction with pegylated interferon. Also, in pregnant females who have extremely high platelets, the action of interferon is slow to bring down the platelets; plateletpheresis was reported to be an option to reduce the number of platelets.

Apart from this, the other treatment recommendations in young women wishing to become pregnant or are pregnant include once-daily aspirin for “very low-risk” or “low-risk” disease and pegylated IFN-α for high-risk disease. Both aspirin and IFN-α therapy are safe for use during pregnancy and might be associated with lower miscarriage rates in women with ET.

According to DelveInsight, Essential Thrombocythemia (ET) 7MM is expected to change in the study period 2017–2030.


Key Findings

• The market size of Essential Thrombocythemia (ET) in the 7MM was found to be USD 616.05 million in 2017.

• Among the 7MM countries, the United States had the highest market size of Essential Thrombocythemia (ET) in 2017, which accounts for approximately 74.03% of the total market.


The United States Market Outlook

This section provides the total Essential Thrombocythemia (ET) market size and; market size by therapies in the United States.


EU-5 Market Outlook

The total Essential Thrombocythemia (ET) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Essential Thrombocythemia (ET) market size and market size by therapies in Japan are provided.


Essential Thrombocythemia (ET) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Essential Thrombocythemia (ET) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Essential Thrombocythemia (ET) market uptake by drugs; patient uptake by therapies; and sales of each drug.  

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Essential Thrombocythemia (ET) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Essential Thrombocythemia (ET) emerging therapies.

Reimbursement Scenario in Essential Thrombocythemia (ET)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Essential Thrombocythemia (ET) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 


Scope of the Report

• The report covers the descriptive overview of Essential Thrombocythemia (ET), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.

• Comprehensive insight has been provided into the Essential Thrombocythemia (ET) epidemiology and treatment.

• Additionally, an all-inclusive account of both the current and emerging therapies for Essential Thrombocythemia (ET) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of Essential Thrombocythemia (ET) market; historical and forecasted is included in the report, covering the 7MM drug outreach.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Essential Thrombocythemia (ET) market.


Report Highlights

• In the coming years, Essential Thrombocythemia (ET) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

• The companies and academics are working to assess challenges and seek opportunities that could influence Essential Thrombocythemia (ET) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• Major players are involved in developing therapies for Essential Thrombocythemia (ET). Launch of emerging therapies will significantly impact the Essential Thrombocythemia (ET) market.

• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


Essential Thrombocythemia (ET) Report Insights

• Patient Population

• Therapeutic Approaches

• Essential Thrombocythemia (ET) Pipeline Analysis

• Essential Thrombocythemia (ET) Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Essential Thrombocythemia (ET) Report Key Strengths

• Eleven Years Forecast

• 7MM Coverage

• Essential Thrombocythemia (ET) Epidemiology Segmentation

• Key Cross Competition

• Highly Analyzed Market

• Drugs Uptake


Essential Thrombocythemia (ET) Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Questions


Market Insights:

• What was the Essential Thrombocythemia (ET) market share (%) distribution in 2017 and how it would look like in 2030?

• What would be the Essential Thrombocythemia (ET) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?

• What are the key findings pertaining to the market across the 7MM and which country will have the largest Essential Thrombocythemia (ET) market size during the forecast period (2020–2030)?

• At what CAGR, the Essential Thrombocythemia (ET) market is expected to grow at the 7MM level during the forecast period (2020–2030)?

• What would be the Essential Thrombocythemia (ET) market outlook across the 7MM during the forecast period (2020–2030)?

• What would be the Essential Thrombocythemia (ET) market growth till 2030 and what will be the resultant market size in the year 2030?

• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

• What is the disease risk, burden and unmet needs of Essential Thrombocythemia (ET)?

• What is the historical Essential Thrombocythemia (ET) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?

• What would be the forecasted patient pool of Essential Thrombocythemia (ET) at the 7MM level?

• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Essential Thrombocythemia (ET)?

• Out of the above-mentioned countries, which country would have the highest prevalent population of Essential Thrombocythemia (ET) during the forecast period (2020–2030)?

• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Essential Thrombocythemia (ET) along with the approved therapy?

• What are the current treatment guidelines for the treatment of Essential Thrombocythemia (ET) in the US and Europe?

• What are the Essential Thrombocythemia (ET) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?

• How many companies are developing therapies for the treatment of Essential Thrombocythemia (ET)?

• How many therapies are developed by each company for the treatment of Essential Thrombocythemia (ET)?

• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Essential Thrombocythemia (ET)?

• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Essential Thrombocythemia (ET) therapies?

• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Essential Thrombocythemia (ET) and their status?

• What are the key designations that have been granted for the emerging therapies for Essential Thrombocythemia (ET)?

• What are the 7MM historical and forecasted market of Essential Thrombocythemia (ET)?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Essential Thrombocythemia (ET).
  • To understand the future market competition in the Essential Thrombocythemia (ET) market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Essential Thrombocythemia (ET) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Essential Thrombocythemia (ET) market.
  • To understand the future market competition in the Essential Thrombocythemia (ET) market.


What is Essential Thrombocythemia? 

Essential Thrombocythemia is uncommon blood cancer, is one of the classic myeloproliferative neoplasms. It is a condition in which the bone marrow produces too many platelets. 

 

What was the Essential Thrombocythemia market size in the 7 major markets (MM) in 2017? 

Essential Thrombocythemia market size in 7MM was USD 616.05 million in 2017.  

 

What was the total prevalent population of Essential Thrombocythemia in the 7MM in 2017? 

The total Essential Thrombocythemia prevalent population in 7MM was 232,688 in 2017. 

 

What are the market drivers of Essential Thrombocythemia?

The rich emerging pipeline, Updated diagnostic criteria, Reach of bone marrow biopsy, and Research and Development are Essential Thrombocythemia market drivers

 

What are the market barriers of Essential Thrombocythemia?

Low disease understanding, Generics of approved drugs, Complications with the available treatment options, and Lack of disease awareness are Essential Thrombocythemia market barriers

 

Which are the emerging therapies in the Essential Thrombocythemia market?

Ropeginterferon alfa-2b (P1101), Jakavi (ruxolitinib), Bomedemstat (IMG-7289), Gandotinib (LY2784544), Imetelstat, Givinostat (ITF2357), Anagrelide Controlled Release/GALE-401 are the emerging therapies in the Essential Thrombocythemia market. 

 

Which are the leading companies in the Essential Thrombocythemia market? 

PharmaEssentia, Novartis, Imago BioSciences, Eli Lilly and Company, Geron Corporation, Italfarmaco, Galena Biopharma are the leading companies in the Essential Thrombocythemia market

 

How is epidemiology segmented for Essential Thrombocythemia?  

Essential Thrombocythemia is segmented as Total Prevalent Cases of Essential Thrombocythemia, Prevalence of Essential Thrombocythemia Based on Symptoms, Gender-specific Prevalence of Essential Thrombocythemia, Age-specific Prevalence of Essential Thrombocythemia, Prevalence of Essential Thrombocythemia Cases Based on Risk, and Gene Mutation specific Prevalence of Essential Thrombocythemia in 7MM from 2017 to 2030.

1. Key Insights

2. Executive Summary of Essential Thrombocythemia (ET)

3. Essential Thrombocythemia (ET): Market Overview at a Glance

3.1. Total Market Share (%) Distribution of ET in 2017

3.2. Total Market Share (%) Distribution of ET in 2030

4. Disease Background and Overview: Essential Thrombocythemia (ET)

4.1. Introduction

4.2. Symptoms

4.3. Causes

4.4. Risk Factors

4.5. Pathogenesis

4.6. Diagnosis of ET

4.6.1. 2016 World Health Organization Diagnostic Criteria for Essential Thrombocythemia

4.6.2. Diagnostic criteria of essential thrombocythemia by the British Committee for Standards in Haematology

4.6.3. International Prognostic Score for Thrombosis in Essential Thrombocythemia

4.6.4. Diagnostic algorithm

5. Case Reports

5.1. A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge

5.2. Case Report: Headache in a Postpartum Patient with Essential Thrombocytosis

5.3. Essential Thrombocythemia in a young man treated for myocardial infarction

5.4. Next-generation sequencing redefines a triple-negative Essential Thrombocythemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots

5.5. JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

6.3. Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM

7. United States Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Essential Thrombocythemia (ET) in the United States

7.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the United States

7.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in the United States

7.5. Age-specific Diagnosed Prevalence of ET in the United States

7.6. Prevalence of ET Cases Based on Risk in the United States

7.7. Gene Mutation specific Prevalence of ET in the United States

8. EU5 Epidemiology

8.1. Germany Epidemiology

8.1.1. Assumptions and Rationale

8.1.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Germany

8.1.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany

8.1.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Germany

8.1.5. Age-specific Diagnosed Prevalence of ET in Germany

8.1.6. Prevalence of ET Cases Based on Risk in Germany

8.1.7. Gene Mutation specific Prevalence of ET in Germany

8.2. France Epidemiology

8.2.1. Assumptions and rationale

8.2.2. Total Prevalent Population of Essential Thrombocythemia (ET) in France

8.2.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France

8.2.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in France

8.2.5. Age-specific Diagnosed Prevalence of ET in France

8.2.6. Prevalence of ET Cases Based on Risk in France

8.2.7. Gene Mutation specific Prevalence of ET in France

8.3. Italy Epidemiology

8.3.1. Assumptions and Rationale

8.3.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Italy

8.3.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy

8.3.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Italy

8.3.5. Age-specific Diagnosed Prevalence of ET in Italy

8.3.6. Prevalence of ET Cases Based on Risk in Italy

8.3.7. Gene Mutation specific Prevalence of ET in Italy

8.4. Spain Epidemiology

8.4.1. Assumptions and Rationale

8.4.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Spain

8.4.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain

8.4.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Spain

8.4.5. Age-specific Diagnosed Prevalence of ET in Spain

8.4.6. Prevalence of ET Cases Based on Risk in Spain

8.4.7. Gene Mutation specific Prevalence of ET in Spain

8.5. United Kingdom Epidemiology

8.5.1. Assumptions and Rationale

8.5.2. Total Prevalent Population of Essential Thrombocythemia (ET) in the UK

8.5.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK

8.5.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in the UK

8.5.5. Age-specific Diagnosed Prevalence of ET in the UK

8.5.6. Prevalence of ET Cases Based on Risk in the UK

8.5.7. Gene Mutation specific Prevalence of ET in the UK

9. Japan Epidemiology

9.1. Assumptions and Rationale

9.2. Total Prevalent Population of Essential Thrombocythemia (ET) Japan

9.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan

9.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Japan

9.5. Age-specific Diagnosed Prevalence of ET in Japan

9.6. Prevalence of ET Cases Based on Risk in Japan

9.7. Gene Mutation specific Prevalence of ET in Japan

10. Current Treatment and Medical Practices

10.1. Risk categories of patients with ET

10.2. Treatment of Essential Thrombocythemia (ET)

10.3. Treatment Algorithm

10.4. Treatment Guidelines

10.4.1. National Comprehensive Cancer Network Guidelines

10.4.2. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

10.4.3. UCLP Myeloproliferative Neoplasms Group: Essential Thrombocythaemia Guideline

10.4.4. The Japanese Society of Hematology guidelines for the treatment of Essential Thrombocythaemia

11. Unmet Needs

12. Marketed Drugs

12.1. Agrylin/Xagrid: Shire

12.1.1. Product Description

12.1.2. Regulatory Milestones

12.1.3. Safety and Efficacy

12.1.4. Product Profile

12.2. Thromboreductin: AOP Orphan Pharmaceuticals

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Safety and Efficacy

12.2.4. Product Profile

13. Emerging Therapies

13.1. Ropeginterferon alfa-2b (P1101): PharmaEssentia

13.1.1. Product Description

13.1.2. Other Developmental Activities

13.1.3. Clinical Development

13.1.4. Product Profile

13.2. Jakavi (ruxolitinib): Novartis

13.2.1. Product Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Safety and Efficacy

13.2.5. Product Profile

13.3. Bomedemstat (IMG-7289): Imago BioSciences

13.3.1. Product Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.4. Safety and Efficacy

13.3.5. Product Profile

13.4. Gandotinib (LY2784544): Eli Lilly and Company

13.4.1. Product Description

13.4.2. Clinical Development

13.4.3. Safety and Efficacy

13.4.4. Product Profile

13.5. Imetelstat: Geron Corporation

13.5.1. Product Description

13.5.2. Other Developmental Activities

13.5.3. Clinical Development

13.5.4. Safety and Efficacy

13.5.5. Product Profile

13.6. Givinostat (ITF2357): Italfarmaco

13.6.1. Product Description

13.6.2. Other Developmental Activities

13.6.3. Clinical Development

13.6.4. Safety and Efficacy

13.6.5. Product Profile

13.7. Anagrelide Controlled Release/GALE-401: Galena Biopharma

13.7.1. Product Description

13.7.2. Other Developmental Activities

13.7.3. Clinical Development

13.7.4. Safety and Efficacy

13.7.5. Product Profile

14. Essential Thrombocythemia (ET): 7MM Market Analysis

14.1. Key Findings

14.2. Market Size of Essential Thrombocythemia (ET) in the 7MM

14.3. Market Size of Essential Thrombocythemia (ET) by Therapies in the 7MM

15. United States

15.1. United States: Market Outlook

15.2. United States Market Size

15.2.1. Total Market size of Essential Thrombocythemia (ET) in the US

15.2.2. Market Size of Essential Thrombocythemia (ET) by Therapies in the US

16. EU-5 countries

16.1. EU-5 Market Outlook

16.2. Germany Market Size

16.2.1. Total Market size of Essential Thrombocythemia (ET) in Germany

16.2.2. Market Size of Essential Thrombocythemia (ET) by therapies in Germany

16.3. France Market Size

16.3.1. Total Market size of Essential Thrombocythemia (ET) in France

16.3.2. Market Size of Essential Thrombocythemia (ET) by therapies in France

16.4. Italy Market Size

16.4.1. Total Market size of Essential Thrombocythemia (ET) in Italy

16.4.2. Market Size of Essential Thrombocythemia (ET) by therapies in Italy

16.5. Spain Market Size

16.5.1. Total Market size of Essential Thrombocythemia (ET) in Spain

16.5.2. Market Size of Essential Thrombocythemia (ET) by therapies in Spain

16.6. United Kingdom Market Size

16.6.1. Total Market size of Essential Thrombocythemia (ET) in the United Kingdom

16.6.2. Market Size of Essential Thrombocythemia (ET) by therapies in the UK

17. Japan

17.1. Market Outlook

17.2. Japan Market Size

17.2.1. Total Market size of Essential Thrombocythemia (ET) in Japan

17.2.2. Market Size of Essential Thrombocythemia (ET) by therapies in Japan

18. Market Drivers

19. Market Barriers

20. Reimbursement and Market Access

21. SWOT Analysis

22. KOL Views

23. Appendix

24. Bibliography

24.1. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

Table 1 Summary of Essential Thrombocythemia (ET), Market, Epidemiology and Key Events (2017–2030)

Table 2 Distribution of mutation in ET patients

Table 3 WHO criteria for the diagnosis of ET

Table 4 Proposed diagnostic criteria for essential thrombocythemia

Table 5 Significant risk factors for thrombosis in patients with WHO-defined ET and associated prognostic scores

Table 6 Risk group and prognosis

Table 7 Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM (2017–2030)

Table 8 Total Prevalent Population of Essential Thrombocythemia (ET) in the US (2017–2030)

Table 9 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the US (2017–2030)

Table 10 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the US (2017–2030)

Table 11 Age-specific Diagnosed Prevalence of ET in the US (2017–2030)

Table 12 Prevalence of ET Based on Risk in the US (2017–2030)

Table 13 Gene Mutation specific Prevalence of ET in the US (2017–2030)

Table 14 Total Prevalent Population of Essential Thrombocythemia (ET) in Germany (2017–2030)

Table 15 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany (2017–2030)

Table 16 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Germany (2017–2030)

Table 17 Age-specific Diagnosed Prevalence of ET in Germany (2017–2030)

Table 18 Prevalence of ET Based on Risk in Germany (2017–2030)

Table 19 Gene Mutation specific Prevalence of ET in Germany (2017–2030)

Table 20 Total Prevalent Population of Essential Thrombocythemia (ET) in France (2017–2030)

Table 21 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France (2017–2030)

Table 22 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in France (2017–2030)

Table 23 Age-specific Diagnosed Prevalence of ET in France (2017–2030)

Table 24 Prevalence of ET Based on Risk in France (2017–2030)

Table 25 Gene Mutation specific Prevalence of ET in France (2017–2030)

Table 26 Total Prevalent Population of Essential Thrombocythemia (ET) in Italy (2017–2030)

Table 27 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy (2017–2030)

Table 28 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Italy (2017–2030)

Table 29 Age-specific Diagnosed Prevalence of ET in Italy (2017–2030)

Table 30 Prevalence of ET Based on Risk in Italy (2017–2030)

Table 31 Gene Mutation specific Prevalence of ET in Italy (2017–2030)

Table 32 Total Prevalent Population of Essential Thrombocythemia (ET) in Spain (2017–2030)

Table 33 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain (2017–2030)

Table 34 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Spain (2017–2030)

Table 35 Age-specific Diagnosed Prevalence of ET in Spain (2017–2030)

Table 36 Prevalence of ET Based on Risk in Spain (2017–2030)

Table 37 Gene Mutation specific Prevalence of ET in Spain (2017–2030)

Table 38 Total Prevalent Population of Essential Thrombocythemia (ET) in the UK (2017–2030)

Table 39 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK (2017–2030)

Table 40 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the UK (2017–2030)

Table 41 Age-specific Diagnosed Prevalence of ET in the UK (2017–2030)

Table 42 Prevalence of ET Based on Risk in the UK (2017–2030)

Table 43 Gene Mutation specific Prevalence of ET in the UK (2017–2030)

Table 44 Total Prevalent Population of Essential Thrombocythemia (ET) in Japan (2017–2030)

Table 45 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan (2017–2030)

Table 46 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Japan (2017–2030)

Table 47 Age-specific Diagnosed Prevalence of ET in Japan (2017–2030)

Table 48 Prevalence of ET Based on Risk in Japan (2017–2030)

Table 49 Gene Mutation specific Prevalence of ET in Japan (2017–2030)

Table 50 NCCN treatment guidelines for ET

Table 51 Ropeginterferon alfa-2b, Clinical Trial Description, 2020

Table 52 Ruxolitinib, Clinical Trial Description, 2020

Table 53 IMG-7289, Clinical Trial Description, 2020

Table 54 LY2784544, Clinical Trial Description, 2020

Table 55 Imetelstat, Clinical Trial Description, 2020

Table 56 Givinostat (ITF2357), Clinical Trial Description, 2020

Table 57 Anagrelide CR, Clinical Trial Description, 2020

Table 58 Market Size of Essential Thrombocythemia (ET) in the 7MM in USD Million (2017–2030)

Table 59 Market Size of Essential Thrombocythemia (ET) by therapies in the 7MM, in USD Million (2017–2030)

Table 60 The US Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)

Table 61 Market Size of Essential Thrombocythemia (ET) by therapies in the US, in USD Million (2017–2030)

Table 62 Germany Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)

Table 63 Market Size of Essential Thrombocythemia (ET) by therapies in Germany, in USD Million (2017–2030)

Table 64 France Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)

Table 65 Market Size of Essential Thrombocythemia (ET) by therapies in France, in USD Million (2017–2030)

Table 66 Italy Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)

Table 67 Market Size of Essential Thrombocythemia (ET) by therapies in Italy, in USD Million (2017–2030)

Table 68 Spain Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)

Table 69 Market Size of Essential Thrombocythemia (ET) by therapies in Spain, in USD Million (2017–2030)

Table 70 The UK Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)

Table 71 Market Size of Essential Thrombocythemia (ET) by therapies in the UK, in USD Million (2017–2030)

Table 72 Japan Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)

Table 73 Market Size of Essential Thrombocythemia (ET) by therapies in Japan, in USD Million (2017–2030)

Figure 1 Laboratory Features of Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis

Figure 2 Common symptoms of ET

Figure 3 Gene mutations in ET

Figure 4 Role of JAK2 in pathway signaling and erythropoietin binding, stem-cell differentiation, and development of homozygosity for the V617F mutation

Figure 5 Diagnostic algorithm for essential thrombocythemia

Figure 6 Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM (2017–2030)

Figure 7 Total Prevalent Population of Essential Thrombocythemia (ET) in the US (2017–2030)

Figure 8 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the US (2017–2030)

Figure 9 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the US (2017–2030)

Figure 10 Age-specific Diagnosed Prevalence of ET in the US (2017–2030)

Figure 11 Prevalence of ET Based on Risk in the US (2017–2030)

Figure 12 Gene Mutation specific Prevalence of ET in the US (2017–2030)

Figure 13 Total Prevalent Population of Essential Thrombocythemia (ET) in Germany (2017–2030)

Figure 14 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany (2017–2030)

Figure 15 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Germany (2017–2030)

Figure 16 Age-specific Diagnosed Prevalence of ET in Germany (2017–2030)

Figure 17 Prevalence of ET Based on Risk in Germany (2017–2030)

Figure 18 Gene Mutation specific Prevalence of ET in Germany (2017–2030)

Figure 19 Total Prevalent Population of Essential Thrombocythemia (ET) in France (2017–2030)

Figure 20 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France (2017–2030)

Figure 21 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in France (2017–2030)

Figure 22 Age-specific Diagnosed Prevalence of ET in France (2017–2030)

Figure 23 Prevalence of ET Based on Risk in France (2017–2030)

Figure 24 Gene Mutation specific Prevalence of ET in France (2017–2030)

Figure 25 Total Prevalent Population of Essential Thrombocythemia (ET) in Italy (2017–2030)

Figure 26 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy (2017–2030)

Figure 27 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Italy (2017–2030)

Figure 28 Age-specific Diagnosed Prevalence of ET in Italy (2017–2030)

Figure 29 Prevalence of ET Based on Risk in Italy (2017–2030)

Figure 30 Gene Mutation specific Prevalence of ET in Italy (2017–2030)

Figure 31 Total Prevalent Population of Essential Thrombocythemia (ET) in Spain (2017–2030)

Figure 32 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain (2017–2030)

Figure 33 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Spain (2017–2030)

Figure 34 Age-specific Diagnosed Prevalence of ET in Spain (2017–2030)

Figure 35 Prevalence of ET Based on Risk in Spain (2017–2030)

Figure 36 Gene Mutation specific Prevalence of ET in Spain (2017–2030)

Figure 37 Total Prevalent Population of Essential Thrombocythemia (ET) in the UK (2017–2030)

Figure 38 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK (2017–2030)

Figure 39 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the UK (2017–2030)

Figure 40 Age-specific Diagnosed Prevalence of ET in the UK (2017–2030)

Figure 41 Prevalence of ET Based on Risk in the UK (2017–2030)

Figure 42 Gene Mutation specific Prevalence of ET in the UK (2017–2030)

Figure 43 Total Prevalent Population of Essential Thrombocythemia (ET) in Japan (2017–2030)

Figure 44 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan (2017–2030)

Figure 45 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Japan (2017–2030)

Figure 46 Age-specific Diagnosed Prevalence of ET in Japan (2017–2030)

Figure 47 Prevalence of ET Based on Risk in Japan (2017–2030)

Figure 48 Gene Mutation specific Prevalence of ET in Japan (2017–2030)

Figure 49 Current treatment algorithm in essential thrombocythemia

Figure 50 Unmet Needs of Essential Thrombocythemia (ET)

Figure 51 Market Size of Essential Thrombocythemia (ET) in the 7MM in USD Million (2017–2030)

Figure 52 Market Size of Essential Thrombocythemia (ET) by therapies in the 7MM, in USD Million (2017–2030)

Figure 53 Market Size of Essential Thrombocythemia (ET) in the US, USD Millions (2017–2030)

Figure 54 Market Size of Essential Thrombocythemia (ET) by therapies in the US, in USD Million (2017–2030)

Figure 55 Market Size of Essential Thrombocythemia (ET) in Germany, USD Millions (2017–2030)

Figure 56 Market Size of Essential Thrombocythemia (ET) by therapies in Germany, in USD Million (2017–2030)

Figure 57 Market Size of Essential Thrombocythemia (ET) in France, USD Millions (2017–2030)

Figure 58 Market Size of Essential Thrombocythemia (ET) by therapies in France, in USD Million (2017–2030)

Figure 59 Market Size of Essential Thrombocythemia (ET) in Italy, USD Millions (2017–2030)

Figure 60 Market Size of Essential Thrombocythemia (ET) by therapies in Italy in USD Million (2017–2030)

Figure 61 Market Size of Essential Thrombocythemia (ET) in Spain, USD Millions (2017–2030)

Figure 62 Market Size of Essential Thrombocythemia (ET) by therapies in Spain in USD Million (2017–2030)

Figure 63 Market Size of Essential Thrombocythemia (ET) in the UK, USD Millions (2017–2030)

Figure 64 Market Size of Essential Thrombocythemia (ET) by therapies in the UK in USD Million (2017–2030)

Figure 65 Market Size of Essential Thrombocythemia (ET) in Japan, USD Millions (2017–2030)

Figure 66 Market Size of Essential Thrombocythemia (ET) by therapies in Japan in USD Million (2017–2030)

Figure 67 Market Drivers

Figure 68 Market Barriers

Figure 69 SWOT analysis of Essential Thrombocythemia

Figure 70 United States KOL Views

Figure 71 EU KOL Views

Figure 72 Japan KOL Views

  • Tags:
  • Essential Thrombocythemia market
  • Essential Thrombocythemia market r...
  • Essential Thrombocythemia market i...
  • Essential Thrombocythemia market t...
  • Essential Thrombocythemia market f...
  • Essential Thrombocythemia market s...
  • Essential Thrombocythemia pipeline...
  • Essential Thrombocythemia treatmen...
  • Essential Thrombocythemia drugs
  • Essential Thrombocythemia sales fo...
  • Essential Thrombocythemia market s...
  • Essential Thrombocythemia disease
  • Essential Thrombocythemia epidemio...
  • Essential Thrombocythemia

Forward to Friend

Need A Quote